Berlin Startup Sanity Group Acquired by Organigram in Major European Cannabis Move
Berlin-based Sanity Group GmbH has completed its acquisition by Organigram Global Inc, marking one of the most significant recent deals in the Berlin tech and healthcare startup ecosystem.
The transaction values Sanity Group at up to €250 million, including an initial €130 million and an additional €120 million tied to performance targets through April 2027. The deal is among the largest in Europe’s cannabis and digital health sector, highlighting Berlin’s growing role as a hub for regulated health innovation.
“The completion of this transaction marks an important next step,” said Finn Hänsel. He added that expanded research and development capabilities and increased production capacity would allow the company “to significantly accelerate and scale our activities in Germany and across Europe.”
The acquisition brings together Sanity Group’s regulatory expertise and European market knowledge with Organigram’s production scale and experience as a licensed cannabis producer. The combined company aims to expand across key European markets, including Germany, while strengthening supply chains and product development.
Sanity Group will continue operating from Berlin with its existing team and brands, focusing on scaling its European platform. The company said pharmacy partners and customers are expected to benefit from increased innovation capacity and broader international integration.
As part of the agreement, Max Narr has joined Organigram’s board during the earnout period. His appointment is intended to ensure European market representation as the combined business expands.
“Sanity Group was founded on the conviction that a sustainable medical cannabis market will emerge in Europe,” Hänsel said, pointing to early investments in supply chains, brand development, and regulatory expertise as key to long-term growth.
From Organigram’s side, CEO James Yamanaka described the deal as “the beginning of the next chapter” in building a global cannabis company. He said the combined entity would have the scale and infrastructure to compete across both Canada and Europe.
Sanity Group will continue prioritising medical cannabis and patient care, while expanding into additional European markets such as the UK, Poland, the Czech Republic, and Switzerland. Hänsel said the company aims to improve access to medical cannabis and further professionalise patient care across the region.
The deal reflects broader momentum in Berlin’s tech and healthcare sectors, where startups are increasingly attracting international investment in regulated industries such as digital health and pharmaceuticals.
